Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03607071
Other study ID # SSc-KKU
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 15, 2018
Est. completion date June 30, 2019

Study information

Verified date September 2020
Source Khon Kaen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary myocardial involvement is common in scleroderma, effected to pericardium, vascular, conducting defect and especially myocardium. Cardiac MRI is widely used for assessment of cardiac involvement in scleroderma, both structural and functional pathology. Cardiac MRI has a diagnostic accuracy of 85% for the detection of myocardial inflammation. Nowadays, the treatment of myocardial inflammation in scleroderma is uncertain. The investigator's study aims to define the cardiac outcome after moderate dose steroid therapy in the patients who have myocardial inflammation detection by cardiac MRI.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 30, 2019
Est. primary completion date June 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

• The adult scleroderma patients who were defined as having myocardial inflammation by cardiac MRI.

Exclusion Criteria:

- Current infection that needs systemic antibiotic therapy

- Active viral hepatitis B or C

- Uncontrolled diabetes mellitus

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prednisolone and taper
Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.

Locations

Country Name City State
Thailand Department of Medicine, Faculty of Medicine, Khon Kaen University Khon Kaen

Sponsors (1)

Lead Sponsor Collaborator
Khon Kaen University

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changing of degree of myocarditis evaluated by cardiac MRI after treatment compare to baseline Myocarditis is defined as inflammatory disease of the myocardium according to the cardiac MRI Lake Louise criteria at least 2 of the following criteria:
Regional or global myocardial signal intensity increased in the T2-weighted images;
Increased global myocardial early enhancement ratio between the myocardium and skeletal muscle in the gadolinium-enhanced T1-weighted images; and,
At least 1 focal lesion with nonischemic regional distribution in the inversion-recovery-prepared, gadolinium-enhanced, T1-weighted images (delayed enhancement).
Response to treatment is defined as any reducing of degree of myocarditis without any progression of myocardial fibrosis or scarring when compared to the cardiac MRI baseline
24 weeks
See also
  Status Clinical Trial Phase
Completed NCT04322630 - Mer-TK in Human Cardiac Cells
Completed NCT03776682 - Myocardial Inflammation in Rheumatoid Arthritis: A Descriptive Study
Completed NCT04940650 - COUREUR Study Myocardial Inflammation in Cyclist Part 1 N/A
Terminated NCT03619876 - Effects of Abatacept on Myocarditis in Rheumatoid Arthritis Phase 4
Completed NCT05138003 - COUREUR Study Myocardial Inflammation in Cyclist Part 2 N/A
Completed NCT03782259 - Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2 Phase 4
Recruiting NCT03525639 - CMR Evaluation of Myocardial Inflammation Persistence After Acute Myocarditis: Prognostic Relevance N/A
Terminated NCT03103490 - 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation Phase 2
Completed NCT04437927 - Impact of 100mL Lipid Emulsion for Intravenous for Suppression of Myocardial Glucose Metabolism in 18F-FDG PET/CT
Recruiting NCT05519735 - Lymphatic Organs and Myocardium After Myocardial Infarction N/A